Dual GIP/GLP-1 receptor agonist. Enhances insulin secretion, reduces glucagon, slows gastric emptying, and acts on hypothalamic appetite centers. Produces greater weight loss than semaglutide in head-to-head trials. Also improves cardiovascular risk markers.
Interactions
Delays absorption of oral medications
Potentiates insulin/sulfonylurea hypoglycemia
May affect oral contraceptive absorption
Contraindications
Personal/family history of medullary thyroid carcinoma
MEN2 syndrome
Pancreatitis history
Severe GI disease
Key Papers
Jastreboff et al. 2022 - SURMOUNT-1 trial (NEJM)
Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.
Should Tirzepatide Be in Your Stack?
Take the free assessment and get personalized recommendations based on your biology and goals.